Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems

Kelly A. Berg, Brian D. Stout, Jodie D. Cropper, Saul Maayani and William P. Clarke
Molecular Pharmacology May 1999, 55 (5) 863-872;
Kelly A. Berg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian D. Stout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jodie D. Cropper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saul Maayani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William P. Clarke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In cell systems where ligand-independent receptor activity is optimized (such as when receptors are overexpressed or mutated), acute treatment with inverse agonists reduces basal effector activity whereas prolonged exposure leads to sensitization of receptor systems and receptor up-regulation. Few studies, however, have reported effects of inverse agonists in systems where nonmutated receptors are expressed at relatively low density. Here, we investigated the effects of inverse agonists at human serotonin (5-HT)2C receptors expressed stably in Chinese hamster ovary cells (≈250 fmol/mg protein). In these cells, there is no receptor reserve for 5-HT and 5-HT2C inverse agonists did not reduce basal inositol phosphate (IP) accumulation nor arachidonic acid (AA) release but behaved as simple competitive antagonists, suggesting that these receptors are not overexpressed. Prolonged treatment (24 h) with inverse agonists enhanced selectively 5-HT2C-mediated IP accumulation but not AA release. The enhancing effect occurred within 4 h of treatment, reversed within 3 to 4 h (after 24-h treatment), and could be blocked with neutral antagonists or weak positive agonists. The enhanced responsiveness was not due to receptor up-regulation but may involve changes in the expression of the G protein, Gαq/11 and possibly Gα12 and Gα13. Interestingly, 24-h exposure to inverse agonists acting at 5-HT2C receptors also selectively enhanced IP accumulation, but not AA release, elicited by activation of endogenous purinergic receptors. These data suggest that actions of inverse agonists may be mediated through effects on receptor systems that are not direct targets for these drugs.

Footnotes

  • Send reprint requests to: Kelly A. Berg, Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284-7764. E-mail: berg{at}uthscsa.edu

  • ↵1 It should be noted however, that Gether et al. (1997) reported that agonists, inverse agonists, and neutral antagonists could up-regulate expression of constitutively active mutants of the β2-adrenergic receptor in Sf9 cells when cells were incubated with ligand during the 48-h infection period. Similar results were reported by Samama et al. (1997) for β2 constitutively active mutants expressed in hearts of transgenic mice. These results were interpreted as due to biochemical stabilization of an inherently unstable, constitutively active receptor. Thus, at least in this treatment paradigm with mutant receptors, up-regulation of receptor density may occur through mechanisms other than by reduction in the activity of effector mechanisms involved in down-regulation.

  • This work was supported by United States Public Health Service Grants DA 09094 (K.A.B., S.M.) and HD 26437 (W.P.C.). Portions of this work have been presented at the first International Union of Pharmacology Conference on Receptor Mechanisms: Principles of Agonism, Merano, Italy (1998), the fourth International Union of Pharmacology Satellite Meeting on Serotonin, Rotterdam, the Netherlands (1998) and at the annual meetings of the Society for Neuroscience (1997, 1998).

  • Abbreviations:
    5-HT
    serotonin
    5-MXG
    5-methoxygramine
    AA
    arachidonic acid
    BOL
    bromo-lysergic acid diethylamide
    CHO
    Chinese hamster ovary
    DMSO
    dimethyl sulfoxide
    DOI
    (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
    HBSS
    Hanks’ balanced salt solution
    IP
    inositol phosphate
    PKC
    protein kinase C
    PLA2
    phospholipase A2
    PLC
    phospholipase C
    5-HT2C
    serotonin type 2C
    BSA
    bovine serum albumin
    PVDF
    polyvinylidene fluoride
    PBS-T
    PBS containing 0.01% Tween-20
    • Received April 1, 1998.
    • Accepted January 27, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 55 (5)
Molecular Pharmacology
Vol. 55, Issue 5
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems

Kelly A. Berg, Brian D. Stout, Jodie D. Cropper, Saul Maayani and William P. Clarke
Molecular Pharmacology May 1, 1999, 55 (5) 863-872;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems

Kelly A. Berg, Brian D. Stout, Jodie D. Cropper, Saul Maayani and William P. Clarke
Molecular Pharmacology May 1, 1999, 55 (5) 863-872;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
  • Relapsed-Leukemia Model with NT5C2/PRPS1 Hotspot Mutations
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics